| Co-Investigator(Kenkyū-buntansha) |
佐藤 悠佑 東京大学, 医学部附属病院, 講師 (20372378)
牧島 秀樹 京都大学, 医学研究科, 准教授 (40402127)
南谷 泰仁 京都大学, 医学研究科, 特定准教授 (60451811)
江藤 浩之 京都大学, iPS細胞研究所, 教授 (50286986)
|
|---|
| Budget Amount *help |
¥238,810,000 (Direct Cost: ¥183,700,000、Indirect Cost: ¥55,110,000)
Fiscal Year 2019: ¥42,250,000 (Direct Cost: ¥32,500,000、Indirect Cost: ¥9,750,000)
Fiscal Year 2018: ¥42,380,000 (Direct Cost: ¥32,600,000、Indirect Cost: ¥9,780,000)
Fiscal Year 2017: ¥42,380,000 (Direct Cost: ¥32,600,000、Indirect Cost: ¥9,780,000)
Fiscal Year 2016: ¥42,250,000 (Direct Cost: ¥32,500,000、Indirect Cost: ¥9,750,000)
Fiscal Year 2015: ¥69,550,000 (Direct Cost: ¥53,500,000、Indirect Cost: ¥16,050,000)
|
|---|
| Outline of Final Research Achievements |
In order to elucidate the evolution and diversity of cancer, we analyzed apparently normal tissues and different stages of cancers using innovative methods such as micro-sampling and single cell culture. We revealed how genetic abnormalities are accumulated by aging, inflammation, smoking, drinking and disease progression. In addition, important structural abnormalities in the untranslated region were identified by whole-genome sequencing. We also revealed the risk of important germ-line mutations in a large-scale sequence in healthy individuals and identified important biomarkers in clinical sequences.
|
